Abiopharma

🔍 Nesci James D (Director)

Company: Blue Foundry Bancorp (BLFY)

Report Date: 2026-03-25

Detailed Transactions and Holdings:

• Acquired 57,045 shares of Common Stock (Direct)
  Date: 2026-03-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 193,475.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 80,297 shares of Common Stock at $13.6435 per share (Direct)
  Date: 2026-03-25 | Code: F | equity_swap_involved: 0 | shares_owned_after: 113,178.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-25 | Code: H | nature_of_ownership: By IRA | shares_owned_after: 36,882.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-25 | Code: H | nature_of_ownership: By ESOP | shares_owned_after: 11,772.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-25 | Code: H | nature_of_ownership: By 401(k) | shares_owned_after: 8,500.00
• Holds 570,450 shares of Stock Options at $11.69 per share (Derivative)
  Date: 2026-03-25 | Code: H | Expires: 2032-10-19 | Exercise: 2023-10-19 | shares_owned_after: 570,450.00 | Footnotes: F3

Footnotes:

• F1: Vesting of performance shares at target in accordance with the Agreement and Plan of Merger by and between Fulton Financial Corporation and Blue Foundry Bancorp.
• F2: Represents shares withheld by the issuer to satisfy tax obligations.
• F3: Stock options vest ratably for seven years commencing on October 19, 2023.